

MIDAS™ Fact Sheet



PALATIN
TECHNOLOGIES, INC.

MIDAS™

Palatin's
proprietary
drug discovery
platform
technology


MIDAS™ (Metal Ion-Induced Distinctive Array of Structure) is a rational, synthetic platform for drug design and discovery. The MIDAS™ system provides a rapid and efficient process to transform peptides into novel pharmaceuticals that either mimic the activity of peptides (peptidomimetic leads) or small molecule therapeutics.

Naturally occurring peptides are highly flexible and exist in multiple conformations. This conformational variability allows interaction with multiple cellular receptor subtypes and often results in numerous bioactivities. Typically, it is difficult to determine the specific peptide conformation that promotes a desired bioactivity, or inactivity, at a receptor site. A key feature of MIDAS™ is its ability to quickly and easily identify, and then stabilize, a desired conformation for a specific drug target.

Various bioactive conformations of a peptide are systematically evaluated through a MIDAS™ process called a "conformational walk". During the conformational walk, a small focused set of stable metallo-peptide structures is created from which drug leads are identified for development. These new MIDAS™ molecules can serve as a starting point for the design of peptidomimetics or small molecule therapeutics. MIDAS™ drug development is inherently enabled due to the rich structure activity relationship (SAR) data it provides and the well-defined predictable structures of its precursor molecules. The next step in the MIDAS™ process is to screen a tailored set of peptidomimetics or small molecules to identify drug leads. These newly identified new chemical entities (NCEs) offer the biological activity of a peptide yet do not have the drug development limitations associated with peptides.

MIDAS™ OFFERS DISTINCT BENEFITS

- MIDAS™ is capable of generating leads with enormous structural diversity because of its ability to incorporate both natural and synthetic building blocks. This structural diversity offers the potential to create new peptidomimetic therapeutics and traditional small molecule therapeutics.
- MIDAS™ can quickly generate both **receptor agonists** (drugs that promote a particular response) and **receptor antagonists** (drugs that block a particular response). It is often difficult using traditional combinatorial drug discovery methods to generate agonists.
- MIDAS™ elegant process and streamlined algorithms improve the productivity of the drug discovery process by eliminating the need for costly and time consuming high-throughput screening, x-ray crystallography, NMR (nuclear magnetic resonance), CADD (computer assisted drug design), or other laboratory and in silico tools currently used for structure-based drug design.



CONTACT

Stephen T. Wills, CPA/MST
Palatin Technologies
EVP - Operations, Chief Financial Officer
(609) 495-2200
info@palatin.com

Palatin is now providing access to the MIDAS™ technology on a collaborative partnership basis.